Antonio Rodríguez-Ariza

12PUBLICATIONS
26CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Medical biochemistry - nucleic acids
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 03, 2026
NR3C1, LAX1, and RCAN3 as Circulating Epigenetic Biomarkers for Prognosis and Chemotherapy Response Prediction in Metastatic Pancreatic Cancer.

Pablo Cano-Ramírez, Marta Toledano-Fonseca, María Teresa Cano-Osuna

|Aug 28, 2025
Immune Modulation Through KIR-HLA Interactions Influences Cetuximab Efficacy in Colorectal Cancer.

María Gómez-Aguilera, Bárbara Manzanares-Martín, Arancha Cebrián-Aranda

|Jun 10, 2025
Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement.

Carmen Navarrete-Sirvent, Ana Mantrana, Aurora Rivas-Crespo

|Jan 11, 2025
Gut Microbiota Interacts with Dietary Habits in Screenings for Early Detection of Colorectal Cancer.

Ana Vega-Rojas, Carmen Haro, Helena Molina-Abril

|Apr 05, 2023
Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancer.

Rafael Mena-Osuna, Ana Mantrana, Silvia Guil-Luna

|Jul 09, 2022
Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab.

M José Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna

Pageof 2

Frequent Collaborators

6 joint publications

Silvia Guil-Luna

6 joint publications

Marta Toledano-Fonseca

3 joint publications

Enrique Aranda

2 joint publications

Rafael Mena-Osuna